Pharma Microbiology Testing Kits Market Report 2025

This Pharma Microbiology Testing Kits market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The pharma microbiology testing kits market size has grown strongly in recent years. It will grow from $6.77 billion in 2024 to $7.26 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to growing demand for pharmaceuticals, increasing prevalence of infectious diseases, rising globalization, rising awareness of the importance of pharma microbiology testing, globalization of pharmaceutical production.

The pharma microbiology testing kits market size is expected to see rapid growth in the next few years. It will grow to $10.78 billion in 2029 at a compound annual growth rate (CAGR) of 10.4%. The growth in the forecast period can be attributed to increasing use of automation in pharma microbiology testing, rising investment in pharma microbiology testing research and development, growing adoption of new technologies in pharma microbiology testing, biopharmaceutical manufacturing, personalized medicine. Major trends in the forecast period include rapid microbial testing, point-of-care testing, single-use systems, digital integration, biosafety and biosecurity.

The pharma microbiology testing kits market is being propelled by the surge in infectious diseases globally. Diseases like Hepatitis A, B, and C, STDs, and HIV are on the rise, as highlighted by the CDC. In 2021, The WHO report noted approximately 1.4 million annual cases of Hepatitis A worldwide. Factors such as infected needle injections, unprotected sex, homelessness, and limited medical access contribute to the escalating instances of infectious diseases, thereby driving the demand for pharma microbiology testing kits.

The rising healthcare expenditure is expected to advance the pharma microbiology testing kits market. Healthcare expenditure encompasses the total amount spent by individuals, organizations, or governments on healthcare-related goods and services over a specific period. An increase in healthcare spending leads to a higher demand for pharma microbiology testing kits, as healthcare facilities invest in comprehensive infection control measures. This results in more frequent testing for microbial contaminants and pathogens to ensure patient safety and compliance with regulatory standards. For instance, in November 2023, the Canadian Institute for Health Information, a nonprofit organization based in Canada, projected that total health expenditure would reach $344 billion in 2023, representing a modest growth of 2.8% compared to the previous year. Therefore, the increase in healthcare expenditure will drive growth in the pharma microbiology testing kits market.

Contracting out routine microbiological testing to specialized laboratories is gaining traction within the pharma microbiology testing kits market. This outsourcing strategy ensures stringent quality and safety standards for raw materials, intermediates, and end products. Contract testing labs manage various testing domains like stability testing, method validation, microbial testing, and batch-release testing. Notably, the global healthcare analytical testing market is projected to reach $4.13 billion by 2021, growing at an 11.3% rate, signaling the expanding reliance on outsourcing for such services.

Major companies in the pharma microbiology testing kits market are increasingly adopting innovative technologies, such as artificial intelligence (AI), to enhance operational efficiency. The use of AI to improve operational efficiency involves leveraging intelligent technologies to boost business performance, streamline processes, reduce costs, and facilitate better decision-making through automation and data analysis. For example, in May 2023, Becton, Dickinson, and Company, a medical device firm based in the U.S., received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its new BD Kiestra MRSA Imaging Application. This application employs artificial intelligence to improve the diagnosis of Methicillin-resistant Staphylococcus aureus (MRSA). It automates the inspection of Petri dishes, a process that has traditionally been labor-intensive and time-consuming, by analyzing bacterial growth on BBL CHROMagar MRSA II plates. The application can swiftly identify specimens that exhibit no significant growth, thereby expediting the processing and release of negative results.

In November 2022, IDEXX, a healthcare innovation company based in the US, acquired Tecta-PDS for an undisclosed sum. This strategic acquisition aims to broaden IDEXX's presence in the field of water microbiology testing. Tecta-PDS, headquartered in Canada, specializes in water microbiology testing services.

Pharma microbiology testing kits play a critical role in identifying contamination and maintaining high standards in pharmaceuticals. These kits are instrumental in detecting microbial limits in drugs, vaccines, and other biologics.

The primary products within pharma microbiology testing kits include consumables and equipment. Consumables are used specifically for detecting microbial limits in pharmaceutical products. These kits facilitate various tests such as endotoxin testing, sterility testing, microbial examination, environmental monitoring, among others. These testing procedures cater to end-users such as hospitals, diagnostic centers, custom lab service providers, academic institutions, and research institutes.

The pharma microbiology testing kits market research report is one of a series of new reports that provides pharma microbiology testing kits market statistics, including pharma microbiology testing kits industry global market size, regional shares, competitors with a pharma microbiology testing kits market share, detailed pharma microbiology testing kits market segments, market trends and opportunities, and any further data you may need to thrive in the pharma microbiology testing kits industry. This pharma microbiology testing kits market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the pharma microbiology testing kits market include F. Hoffmann-La Roche AG, Becton Dickinson and Company, Abbott Laboratories, ThermoFisher Scientific, SGS SA, Toxikon Corp., Pace Analytical Services, Boston Analytics, Charles River Laboratories International, Nelson Laboratories, Siemens healthcare AG, Hologic Inc., Neogen Corporation, Shimadzu Corporation, Merck KGaA, Agilent TechnologiesInc., QIAGEN N.V., Bruker Corporation, bioMérieux SA, Lucideon, Lonza Group AG, MilliporeSigma, Hardy Diagnostics, Sartorius AG, 3M Company, Waters Corporation, PerkinElmer Inc., Luminex Corporation.

North America was the largest region in the pharma microbiology testing kits market in 2024. Western Europe was the second-largest region in the global pharma microbiology testing kits market report. The regions covered in the pharma microbiology testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharma microbiology testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The pharma microbiology testing kits market consists of sales of rapid test systems, common rapid test kits, rapid tests for salmonella, PCR test, and lateral flow. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.